Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients

Launched by ROHAN DHARMAKUMAR · Oct 27, 2022

Keywords

ClinConnect Summary

This clinical trial is exploring whether a medication called Deferiprone can help patients who have experienced a heart attack (specifically, a type known as STEMI) by reducing excess iron in the heart muscle where bleeding has occurred. The researchers are looking to find out if Deferiprone can improve recovery in patients who have had a heart attack that resulted in bleeding within the heart tissue.

To participate in this study, you need to be between 18 and 79 years old and have had a recent heart attack diagnosed according to specific guidelines. There are some important reasons why someone might not be eligible, such as a history of certain heart conditions or recent treatments. If you join the study, you will receive care according to the trial's design, and you will be closely monitored during the treatment. This research is in the early stages, and we hope it can lead to better treatments for heart attack patients in the future.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • 1. Age ≥ 18 years
• • 2. Index Anterior wall STEMI
• • 3. Emergency coronary angiogram with primary PCI
• • Exclusion Criteria
• • 1. Prior history of MI / PCI / coronary artery bypass graft (CABG) within previous 1 year
• • 2. Patients with previous history of left ventricular ejection fraction (LVEF) \< 40%
• • 3. Use of investigational drugs or devices 30 days prior to randomization
• • 4. Known allergy or contra-indication to gadolinium/contrast agents
• • 5. eGFR \< 30 ml/kg/min
• • 6. Any contraindication against cardiac MRI (such as metal implants)
• • 7. Women who are pregnant or breastfeeding. Women of reproductive potential must have a negative pregnancy test prior to randomization
• • 8. Body weight \> 140 kg (or 309 lbs.)
• • 9. Absolute neutrophil count - ANC \< 1.5 k/cumm
• • 10. History of Chronic Liver Disease
• • 11. Elevated hepatic enzymes (BOTH ALT and AST) \> 2 times of upper normal limit
• • 12. Patients with iron storage disease (hemochromatosis, thalassemia) or who are already treated with iron chelators
• • 13. Any clinically significant abnormality identified prior to randomization that in the judgment of the Sponsor-Investigator or Delegate would preclude safe completion of the study or confound the anticipated benefit of deferiprone.
• • 14. Life expectancy of less than 1 year due to non-cardiac pathology